Skip to main content
. Author manuscript; available in PMC: 2022 Jul 22.
Published in final edited form as: J Med Chem. 2021 Dec 13;64(24):18158–18174. doi: 10.1021/acs.jmedchem.1c01671

Figure 7. VD2173 and ZFH7116 overcome HGF-dependent resistance to anti-EGFR and anti-MET inhibition.

Figure 7.

(a) HCC827 lung cancer cells were treated with gefitinib (20 nM) in the absence or presence of pro-HGF (100 ng/ml) and VD2713 or ZFH7116 (0.1-1μM) as indicated, and cell viability was determined after 72hrs by crystal violet staining. Data represent the means±S.E.M. for n=3-5. Statistical analysis was performed using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test and statistical significance is indicated compared to HCC827 cells treated with gefitinib and pro-HGF. ***P<0.001 and ****P<0.0001. (b) EBC-1 lung cancer cells were pre-incubated with pro-HGF (100 ng/ml) in the absence or presence of VD2173 or ZFH7116 (1μM) for 24 hours before treatment with MET kinase inhibitor JNJ-38877605 (JNJ; 25nM). Cell viability was determined after 48 hrs by CellTiterGlo. Data represent the means±S.E.M. for n=3. Statistical analysis was performed using one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test and statistical significance is indicated compared to EBC-1 cells treated with JNJ and pro-HGF. **P<0.01.